Evidence map›Paper›PMID 31394567›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020

Promoting activity of (α4)

Jingyi Wang, Angelo Blasio, Holly L Chapman, Christelle Doebelin, Victor Liaw, Alexander Kuryatov, Simone M Giovanetti, Jon Lindstrom, Li Lin, Michael D Cameron and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jingyi WangDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA. jingyi.wang817@gmail.com.
Angelo BlasioDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA.
Holly L ChapmanDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0001-9739-8024
Christelle DoebelinDepartment of Molecular Medicine, The Scripps Research Institute, Scripps Florida, Jupiter, FL, USA.
Victor LiawDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA.
Alexander KuryatovDepartment of Neuroscience, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Simone M GiovanettiDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA.
Jon LindstromDepartment of Neuroscience, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Li LinDMPK core, The Scripps Research Institute, Scripps Florida, Jupiter, FL, USA.
Michael D CameronDMPK core, The Scripps Research Institute, Scripps Florida, Jupiter, FL, USA.
Theodore M KameneckaDepartment of Molecular Medicine, The Scripps Research Institute, Scripps Florida, Jupiter, FL, USA.
Matthew B PomrenzeDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA.
Robert O MessingDepartments of Neuroscience and Neurology, The University of Texas at Austin, Austin, TX, USA. romessing@austin.utexas.edu.ORCID http://orcid.org/0000-0002-5345-4431
The University of Texas at Austin · USScripps Research Institute · USUniversity of Pennsylvania · US

Funding

Development of a5* nAChR positive allosteric modulators for tobacco dependenceR01DA030929 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI KENNY, PAUL J., LINDSTROM, JON MARTIN · 2011 to 2015
$7.1M
NIDA NIH HHS R01 DA030929
6 · The paper itself

Abstract

There is increasing interest in developing drugs that act at α4β2 nicotinic acetylcholine receptors (nAChRs) to treat alcohol use disorder. The smoking cessation agent varenicline, a partial agonist of α4β2 nAChRs, reduces alcohol intake, but its use can be limited by side effects at high therapeutic doses. There are two stoichiometric forms of α4β2 nAChRs, (α4)

Indexed as

Alcohol DrinkingAnimalsDose-Response Relationship, DrugDrug Therapy, CombinationEthanolFemaleMaleMiceMice, Inbred C57BLMice, Inbred DBANicotinic AgonistsOxadiazolesPyridinesReceptors, NicotinicSelf AdministrationVarenicline3-(3-(pyridine-3-yl)-1,2,4-oxadiazol-5-yl)benzonitrileEthanolNicotinic Agonistsnicotinic receptor alpha4beta2OxadiazolesPyridinesReceptors, NicotinicVarenicline

Identifiers

PMID31394567
PMCPMC6901472
OpenAlexW2965178215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.